A2ti-1 is a selective and high-affinity annexin A2/S100A10 heterotetramer (A2t) inhibitor with an IC50 of 24 μM[1]. A2ti-1 specifically disrupts the protein-protein interaction (PPI) between A2 and S100A10. A2ti-1 prevents human papillomavirus type 16 (HPV16) infection[2].

A2ti-1 (compound 1 b) is an annexin A2-S100A10 protein-protein interaction blocker[1]. A2ti-1 (100 μM; for 72 hours) reduces HPV16 PsV infection of HeLa cells in a dose-dependent manner[2]. A2ti-1 (10, 25, 50, 75, 100 μM; 24 hours) significantly reduces CFDA-SE-labelled HPV16 PsV entry into HeLa cells in a dose-dependent manner[2]. Cell Viability Assay[2] Cell Line: HeLa cells

570390-00-0

C20H22N4O2S

382.48

A2ti-1

DMSO:250 mg/mL (653.63 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years